Table 3.
Pairwise treatment comparisons from network meta-analyses for the outcomes post-treatment depression scores (above the diagonal) and study discontinuation (below the diagonal)
| Ftf CBT | 0.18 | 0.21 | 0.00 | 0.02 | −0.02 | −0.16 | −0.04 | 0.06 | −1.31 | −0.17 | 0.08 | 0.05 | 0.11 | −0.02 | 0.34 |
| −0.09–0.44 | −0.07–0.50 | −0.66–0.67 | −0.21–0.25 | −0.25–0.20 | −0.88–0.55 | −0.31–0.22 | −0.20–0.33 | −2.15–(−0.47) | −0.69–0.35 | −0.29–0.46 | −0.22–0.32 | −0.19–0.41 | −0.56–0.53 | 0.16–0.51 | |
| 1.47 | Ftf PST | 0.04 | −0.17 | −0.16 | −0.20 | −0.34 | −0.22 | −0.11 | −1.48 | −0.35 | −0.09 | −0.13 | −0.06 | −0.19 | 0.16 |
| 0.65–3.51 | −0.23–0.31 | −0.81–0.47 | −0.42–0.11 | −0.48–0.08 | −1.06–0.38 | −0.50–0.06 | −0.39–0.17 | −2.31–(−0.66) | −0.81–0.12 | −0.44–0.25 | −0.34–0.09 | −0.36–0.24 | −0.76–0.37 | −0.04–0.36 | |
| 0.98 | 0.67 | Ftf IPT | −0.21 | −0.19 | −0.24 | −0.38–1.11– | −0.26 | −0.15 | −1.52 | −0.38 | −0.13 | −0.16 | −0.10 | −0.23 | 0.12 |
| 0.30–3.11 | 0.25–1.70 | −0.86–0.44 | −0.48–0.09 | −0.54–0.06 | 0.35 | −0.56–0.05 | −0.45–0.15 | −2.36–(−0.69) | −0.90–0.14 | −0.44–0.17 | −0.41–0.08 | −0.40–0.19 | −0.81–0.34 | −0.11–0.35 | |
| 1.72 | 1.17 | 1.75 | Ftf PDT | 0.02 | −0.03 | −0.17 | −0.05 | 0.06 | −1.31 | −0.17 | 0.08 | 0.05 | 0.11 | −0.02 | 0,33 |
| 0.24–15.2 | 0.18–9.32 | 0.25–14.41 | −0.65–0.68 | −0.70–0.64 | −1.11–0.78 | −0.72–0.62 | −0.61–0.73 | −2.31–(−0.31) | −0.95–0.60 | −0.60–0.75 | −0.56–0.65 | −0.57–0.79 | −0.85–0.81 | −0,31–0,97 | |
| 0.99 | 0.67 | 1.01 | 0.58 | Ftf Other | −0.04 | −0.19 | −0.06 –0.33– | 0.04 | −1.33 | −0.19 | 0.06 | 0.03 | 0.09 | −0.04 | 0.31 |
| 0.48–2.12 | 0.27–1.59 | 0.34–3.07 | 0.07–4.46 | −0.30–0.21 | −0.90–0.53 | 0.20 | −0.22–0.30 | −2.17–(−0.49) | −0.71–0.33 | −0.31–0.43 | −0.24–0.30 | −0.20–0.39 | −0.54–0.46 | 0.14–0.49 | |
| 1.75 | 1.19 | 1.79 | 1.02 | 1.77 | Rtl CBT | −0.14 | −0.02 | 0.09 | −1.29 | −0.15 | 0.11 | 0.07 | 0.14 | 0.01 | 0.36 |
| 0.67–4.46 | 0.36–3.51 | 0.50–6.34 | 0.09–7.89 | 0.59–5.14 | −0.86–0.58 | −0.30–0.26 | −0.19–0.36 | −2.13–(−0.44) | −0.68–0.38 | −0.28–0.49 | −0.21–0.36 | −0.18–0.45 | −0.55–0.57 | 0.17–0.55 | |
| 0.74 | 0.51 | 0.76 | 0.43 | 0.75 | 0.42 | Rtl PST | 0.12 | 0.23 | −1.14 | 0.00 | 0.25 | 0.22 | 0.28 | 0.15 | 0.50 |
| 0.17–3.23 | 0.11–2.22 | 0.15–3.32 | 0.04–4.66 | 0.18–3.21 | 0.08–2.17 | −0.60–0.84 | −0.49–0.95 | −2.22–(−0.07) | −0.86–0.85 | −0.52–1.02 | −0.51–0.94 | −0.46–1.02 | −0.72–1.02 | −0.19–1.19 | |
| 0.62 | 0.42 | 0.63 | 0.36 | 0.63 | 0.35 | 0.83 | Gsh CBT | 0.11 | −1.26 | −0.13 | 0.13 | 0.09 | 0.16 | 0.03 | 0.38 |
| 0.24–1.46 | 0.16–1.00 | 0.20–1.88 | 0.04–2.81 | 0.25–1.56 | 0.11–1.08 | 0.19–3.80 | −0.17–0.39 | −2.11–(−0.42) | −0.66–0.41 | −0.26–0.51 | −0.20–0.38 | −0.17–0.48 | −0.54–0.59 | 0.18–0.58 | |
| 0.66 | 0.45 | 0.68 | 0.39 | 0.67 | 0.38 | 0.89 | 1.07 | Nmc CBT | −1.37 | −0.23 | 0.02 | −0.01 | 0.05 | −0.08 –0.64– | 0.27 |
| 0.21–2.08 | 0.15–1.37 | 0.19–2.16 | 0.04–3.48 | 0.23–1.96 | 0.102–1.43 | 0.18–4.43 | 0.35–3.46 | −2.22–(−0.53) | −0.76–0.30 | −0.37–0.40 | −0.30–0.2 | −0.27–0.37 | 0.48 | 0.07–0.47 | |
| No data | No data | No data | No data | No data | No data | No data | No data | No data | Ftf CBT + SSRI | 1.14 | 1.39 | 1.36 | 1.42 | 1.29 | 1.64 |
| 0.21–2.07 | 0.54–2.24 | 0.56–2.16 | 0.57–2.27 | 0.31–2.27 | 0.82–2.47 | ||||||||||
| 2.04 | 1.39 | 2.08 | 1.19 | 2.06 | 1.16 | 2.74 | 3.29 | 3.07 | No data | Ftf PST + SSRI | 0.25 | 0.22 | 0.28 | 0.15 | 0.50 |
| 0.40–9.99 | 0.34–5.61 | 0.40–10.65 | 0.12–12.2 | 0.40–9.90 | 0.20–6.44 | 0.31–20.2 | 0.65–18.1 | 0.56–16.7 | −0.31–0.81 | −0.26–0.70 | −0.26–0.82 | −0.57–0.88 | 0.01–1.00 | ||
| 1.54 | 1.05 | 1.58 | 0.90 | 1.56 | 0.88 | 2.07 | 2.49 | 2.32 | No data | 0.76 | Ftf IPT + SSRI | −0.03 | 0.03 | −0.10 | 0.25 |
| 0.38–6.64 | 0.29–4.04 | 0.50–5.10 | 0.09–7.19 | 0.39–6.64 | 0.18–4.16 | 0.33–13.7 | 0.55–10.5 | 0.48–12.5 | 0.13–4.68 | −0.33–0.27 | −0.36–0.42 | −0.72–0.53 | −0.08–0.58 | ||
| 1.26 | 0.86 | 1.29 | 0.73 | 1.27 | 0.72 | 1.69 | 2.03 | 1.90 | No data | 0.62 | 0.82 | SSRI | 0.06 | −0.07 | 0.28 |
| 0.52–3.18 | 0.44–1.76 | 0.53–3.20 | 0.11–4.10 | 0.51–3.45 | 0.22–2.39 | 0.39–8.14 | 0.74–5.83 | 0.60–6.77 | 0.16–3.11 | 0.26–2.73 | −0.24–0.37 | −0.64–0.50 | 0.08–0.49 | ||
| 1.54 | 1.05 | 1.58 | 0.90 | 1.56 | 0.88 | 2.08 | 2.49 | 2.33 | No data | 0.76 | 1.00 | 1.23 | TCA | −0.13 | 0.22 |
| 0.45–5.36 | 0.37–3.10 | 0.57–4.37 | 0.09–7.67 | 0.50–5.56 | 0.22–3.54 | 0.40–11.0 | 0.70–9.17 | 0.70–9.57 | 0.13–4.10 | 0.23–4.25 | 0.39–3.90 | −0.71–0.45 | −0.03–0.48 | ||
| 2.01 | 1.37 | 2.06 | 1.17 | 2.03 | 1.15 | 2.71 | 3.25 | 3.04 | No data | 0.99 | 1.31 | 1.60 | 1.30 | Individ.. Antid. | 0.35 |
| 0.40–9.46 | 0.25–7.50 | 0.32–11.74 | 0.08–12.9 | 0.46–8.52 | 0.18–6.73 | 0.35–19.8 | 0.57–18.5 | 0.47–18.4 | 0.10–9.23 | 0.17–9.78 | 0.26–8.45 | 0.21–8.41 | −0.18–0.88 | ||
| 1.00 | 0.68 | 1.03 | 0.59 | 1.01 | 0.57 | 1.35 | 1.62 | 1.51 | No data | 0.49 | 0.65 | 0.80 | 0.65 | 0.50 | UC/placebo |
| 0.57–1.86 | 0.34–1.27 | 0.40–2.39 | 0.08–4.08 | 0.56–1.86 | 0.22–1.45 | 0.36–5.16 | 0.80–3.24 | 0.60–3.76 | 0.11–2.22 | 0.18–2.33 | 0.36–1.60 | 0.21–1.76 | 0.11–2.48 |
With regard to post-treatment depression scores, standardized mean differences above 0 favor the row-defining treatment, and below 0 the column-defining treatment. With regard to study discontinuation, odds ratios smaller than 1 favor the column-defining treatment, and odds ratios lower than 1 favor the row-defining treatment. Reciprocals should be used to obtain odds ratios in the opposite direction. Bold-faced figures indicate a difference between treatments with 95 % credible intervals of estimates excluding 1. For abbreviations see Table 2
The results are standardized mean differences (post-treatment depression scores with 95 % confidence intervals) and odds ratios (study discontinuation with 95 % credible intervals) when comparing the column-defined treatments with the row-defined treatments